Lymphoma

Egesta Lopci, Arnoldo Piccardo

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In pediatric population, approximately 12 % of all malignancies are represented by lymphoma, and of these, the majority are composed of non-Hodgkin lymphoma, whereas 40 % are represented by Hodgkin disease (HD). NHL is more common in younger children and preteen age, whereas HD shows a bimodal age distribution with an initial peak incidence around 14 years of age. A different prognosis is also reported in the two lymphoma types, with over 90-95 % of patients with HD having a 5-year event-free survival upon 70-85 % of NHL patients. Treatment options comprise different combination of chemotherapy regimens and/or consolidation radiotherapy, which can be safely omitted in limited stages and good responders after few cycles of chemotherapy. In this context, instrumental imaging becomes crucial either for disease staging or for a proper treatment response assessment. This fact is confirmed by the introduction of early response to chemotherapy as a predictor to disease outcome in recent trials. As for other malignancies, a significant role in the evaluation of HD and NHL is played by 18F-fluorodeoxyglucose PET (18F-FDG PET). As a noninvasive imaging technique, it allows for a whole-body detection of all lymphatic and extralymphatic sites of disease, resulting superior to other conventional imaging modalities. Moreover, this imaging modality allows a reliable identification of residual tumor after treatment, thus significantly improving treatment planning and overall survival. Therefore, the method is recommended for initial staging and for response assessment of pediatric lymphoma.

Original languageEnglish
Title of host publicationClinical Nuclear Medicine in Pediatrics
PublisherSpringer International Publishing
Pages239-254
Number of pages16
ISBN (Print)9783319213712, 9783319213705
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Hodgkin Disease
Lymphoma
Pediatrics
Drug Therapy
Age Distribution
Fluorodeoxyglucose F18
Residual Neoplasm
Therapeutics
Combination Drug Therapy
Non-Hodgkin's Lymphoma
Disease-Free Survival
Neoplasms
Radiotherapy
Survival
Incidence
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lopci, E., & Piccardo, A. (2015). Lymphoma. In Clinical Nuclear Medicine in Pediatrics (pp. 239-254). Springer International Publishing. https://doi.org/10.1007/978-3-319-21371-2_12

Lymphoma. / Lopci, Egesta; Piccardo, Arnoldo.

Clinical Nuclear Medicine in Pediatrics. Springer International Publishing, 2015. p. 239-254.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lopci, E & Piccardo, A 2015, Lymphoma. in Clinical Nuclear Medicine in Pediatrics. Springer International Publishing, pp. 239-254. https://doi.org/10.1007/978-3-319-21371-2_12
Lopci E, Piccardo A. Lymphoma. In Clinical Nuclear Medicine in Pediatrics. Springer International Publishing. 2015. p. 239-254 https://doi.org/10.1007/978-3-319-21371-2_12
Lopci, Egesta ; Piccardo, Arnoldo. / Lymphoma. Clinical Nuclear Medicine in Pediatrics. Springer International Publishing, 2015. pp. 239-254
@inbook{18e89a67d2a24fa297a2248d520ea335,
title = "Lymphoma",
abstract = "In pediatric population, approximately 12 {\%} of all malignancies are represented by lymphoma, and of these, the majority are composed of non-Hodgkin lymphoma, whereas 40 {\%} are represented by Hodgkin disease (HD). NHL is more common in younger children and preteen age, whereas HD shows a bimodal age distribution with an initial peak incidence around 14 years of age. A different prognosis is also reported in the two lymphoma types, with over 90-95 {\%} of patients with HD having a 5-year event-free survival upon 70-85 {\%} of NHL patients. Treatment options comprise different combination of chemotherapy regimens and/or consolidation radiotherapy, which can be safely omitted in limited stages and good responders after few cycles of chemotherapy. In this context, instrumental imaging becomes crucial either for disease staging or for a proper treatment response assessment. This fact is confirmed by the introduction of early response to chemotherapy as a predictor to disease outcome in recent trials. As for other malignancies, a significant role in the evaluation of HD and NHL is played by 18F-fluorodeoxyglucose PET (18F-FDG PET). As a noninvasive imaging technique, it allows for a whole-body detection of all lymphatic and extralymphatic sites of disease, resulting superior to other conventional imaging modalities. Moreover, this imaging modality allows a reliable identification of residual tumor after treatment, thus significantly improving treatment planning and overall survival. Therefore, the method is recommended for initial staging and for response assessment of pediatric lymphoma.",
author = "Egesta Lopci and Arnoldo Piccardo",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-319-21371-2_12",
language = "English",
isbn = "9783319213712",
pages = "239--254",
booktitle = "Clinical Nuclear Medicine in Pediatrics",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Lymphoma

AU - Lopci, Egesta

AU - Piccardo, Arnoldo

PY - 2015/1/1

Y1 - 2015/1/1

N2 - In pediatric population, approximately 12 % of all malignancies are represented by lymphoma, and of these, the majority are composed of non-Hodgkin lymphoma, whereas 40 % are represented by Hodgkin disease (HD). NHL is more common in younger children and preteen age, whereas HD shows a bimodal age distribution with an initial peak incidence around 14 years of age. A different prognosis is also reported in the two lymphoma types, with over 90-95 % of patients with HD having a 5-year event-free survival upon 70-85 % of NHL patients. Treatment options comprise different combination of chemotherapy regimens and/or consolidation radiotherapy, which can be safely omitted in limited stages and good responders after few cycles of chemotherapy. In this context, instrumental imaging becomes crucial either for disease staging or for a proper treatment response assessment. This fact is confirmed by the introduction of early response to chemotherapy as a predictor to disease outcome in recent trials. As for other malignancies, a significant role in the evaluation of HD and NHL is played by 18F-fluorodeoxyglucose PET (18F-FDG PET). As a noninvasive imaging technique, it allows for a whole-body detection of all lymphatic and extralymphatic sites of disease, resulting superior to other conventional imaging modalities. Moreover, this imaging modality allows a reliable identification of residual tumor after treatment, thus significantly improving treatment planning and overall survival. Therefore, the method is recommended for initial staging and for response assessment of pediatric lymphoma.

AB - In pediatric population, approximately 12 % of all malignancies are represented by lymphoma, and of these, the majority are composed of non-Hodgkin lymphoma, whereas 40 % are represented by Hodgkin disease (HD). NHL is more common in younger children and preteen age, whereas HD shows a bimodal age distribution with an initial peak incidence around 14 years of age. A different prognosis is also reported in the two lymphoma types, with over 90-95 % of patients with HD having a 5-year event-free survival upon 70-85 % of NHL patients. Treatment options comprise different combination of chemotherapy regimens and/or consolidation radiotherapy, which can be safely omitted in limited stages and good responders after few cycles of chemotherapy. In this context, instrumental imaging becomes crucial either for disease staging or for a proper treatment response assessment. This fact is confirmed by the introduction of early response to chemotherapy as a predictor to disease outcome in recent trials. As for other malignancies, a significant role in the evaluation of HD and NHL is played by 18F-fluorodeoxyglucose PET (18F-FDG PET). As a noninvasive imaging technique, it allows for a whole-body detection of all lymphatic and extralymphatic sites of disease, resulting superior to other conventional imaging modalities. Moreover, this imaging modality allows a reliable identification of residual tumor after treatment, thus significantly improving treatment planning and overall survival. Therefore, the method is recommended for initial staging and for response assessment of pediatric lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=84957711156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957711156&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-21371-2_12

DO - 10.1007/978-3-319-21371-2_12

M3 - Chapter

AN - SCOPUS:84957711156

SN - 9783319213712

SN - 9783319213705

SP - 239

EP - 254

BT - Clinical Nuclear Medicine in Pediatrics

PB - Springer International Publishing

ER -